SAM Holdings Forms Strategic Review Committee Amidst Continuing Net Loss
SAM Holdings Forms Strategic Review Committee Amidst Continuing Net Loss
The lower revenue with higher operating expenses has resulted in the group continuing to record net losses, negative working capital, and negative cash flow from operations.Returns from its proton beam therapy have been slower than expected.
其質子束療法的回報比預期的要慢。
The Singapore Institute of Advanced Medicine Holdings (SAM) has formed a strategic review committee (SRC) in its bid to address the company's continuous net loss.
新加坡愛文思控股（SAM）已成立一個戰略審查委員會（SRC），以應對公司持續的淨虧損。
The ramp-up in SAM's business on the proton beam therapy has been slower than expected due to delays in being included on the panels of healthcare providers of insurance companies, low patient flow, and competition.
由於被醫療保險公司選入醫療提供者名單的延遲、患者流量低以及競爭，SAM的質子束療法業務增長速度比預期的要慢。
The lower revenue with higher operating expenses has resulted in the group continuing to record net losses, negative working capital, and negative cash flow from operations.
營業收入降低而營業費用上升導致該集團繼續記錄淨虧損、負流動資金和負經營現金流。
The SRC, comprising of non-executive directors of the company, will assist the executive management team on various ongoing and new initiatives focused on improving proton beam therapy utilisation and photon radiation therapy facilities.
該SRC由公司的非執行董事組成，將協助執行管理團隊進行各種持續和新的舉措，專注於改善質子束療法的利用率和光子放射治療設施。
譯文內容由第三人軟體翻譯。
